Shinpoong PharmaceuticalLtd (A019170) Stock Overview
Manufactures and sells pharmaceutical products in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A019170 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shinpoong Pharmaceutical Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩14,750.00 |
| 52 Week High | ₩20,500.00 |
| 52 Week Low | ₩6,400.00 |
| Beta | 1.32 |
| 1 Month Change | 3.36% |
| 3 Month Change | 16.14% |
| 1 Year Change | 36.70% |
| 3 Year Change | -35.59% |
| 5 Year Change | -89.90% |
| Change since IPO | 676.15% |
Recent News & Updates
What Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) P/S Is Not Telling You
Oct 27
Is Shinpoong PharmaceuticalLtd (KRX:019170) Using Debt In A Risky Way?
Aug 12Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jul 06Recent updates
What Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) P/S Is Not Telling You
Oct 27Is Shinpoong PharmaceuticalLtd (KRX:019170) Using Debt In A Risky Way?
Aug 12Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jul 06Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) 40% Share Price Surge Not Quite Adding Up
May 22Is Shinpoong PharmaceuticalLtd (KRX:019170) Using Debt Sensibly?
Apr 09Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) Share Price Could Signal Some Risk
Jan 06Does Shinpoong PharmaceuticalLtd (KRX:019170) Have A Healthy Balance Sheet?
Nov 13Shinpoong Pharmaceutical Co.,Ltd's (KRX:019170) 30% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Sep 11Is Shinpoong PharmaceuticalLtd (KRX:019170) Weighed On By Its Debt Load?
Aug 08Shinpoong Pharmaceutical Co.,Ltd (KRX:019170) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Apr 24Do Shin Poong Pharm.Co.Ltd's (KRX:019170) Earnings Warrant Your Attention?
Mar 07Declining Stock and Decent Financials: Is The Market Wrong About Shin Poong Pharm.Co.,Ltd. (KRX:019170)?
Feb 01
We Wouldn't Rely On Shin Poong Pharm.Co.Ltd's (KRX:019170) Statutory Earnings As A Guide
Jan 05Is Shin Poong Pharm.Co.Ltd (KRX:019170) Using Too Much Debt?
Dec 10Shareholder Returns
| A019170 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -2.0% | -0.7% | 3.3% |
| 1Y | 36.7% | 37.6% | 67.7% |
Return vs Industry: A019170 matched the KR Pharmaceuticals industry which returned 37.6% over the past year.
Return vs Market: A019170 underperformed the KR Market which returned 67.7% over the past year.
Price Volatility
| A019170 volatility | |
|---|---|
| A019170 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 4.6% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.6% |
Stable Share Price: A019170 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A019170's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 819 | Jei-Man Ryu | shinpoong.co.kr |
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; wound dressings; health functional food; and over the counter products.
Shinpoong Pharmaceutical Co.,Ltd Fundamentals Summary
| A019170 fundamental statistics | |
|---|---|
| Market cap | ₩764.01b |
| Earnings (TTM) | -₩3.71b |
| Revenue (TTM) | ₩231.90b |
Is A019170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A019170 income statement (TTM) | |
|---|---|
| Revenue | ₩231.90b |
| Cost of Revenue | ₩134.86b |
| Gross Profit | ₩97.05b |
| Other Expenses | ₩100.76b |
| Earnings | -₩3.71b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -72.34 |
| Gross Margin | 41.85% |
| Net Profit Margin | -1.60% |
| Debt/Equity Ratio | 18.1% |
How did A019170 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 14:36 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shinpoong Pharmaceutical Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.